Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Hirntumore – Eine Einführung mit dem Fokus auf aktuelle interdisziplinäre Therapiekonzepte

Wolfgang Wick, Frank Winkler, Michael Platen (S. 10-14)

 

  1. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344(6190):1396-401
  2. Riemenschneider, M. J., D. N. Louis, M. Weller and P. Hau. Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. Acta Neuropathol 2013;126(1): 21-37.
  3. Huse, J. T., et al.. High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas. Acta Neuropathol 2011;122(3): 367-369.
  4. Wick, W., M. Platten, C. Meisner, J. Felsberg, G. Tabatabai, M. Simon, G. Nikkhah, K. Papsdorf, J. P. Steinbach, M. Sabel, S. E. Combs, J. Vesper, C. Braun, J. Meixensberger, R. Ketter, R. Mayer-Steinacker, G. Reifenberger and M. Weller. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. The Lancet Oncology 2012;13(7): 707-715.
  5. Malmstrom, A., B. H. Gronberg, C. Marosi, R. Stupp, D. Frappaz, H. Schultz, U. Abacioglu, B. Tavelin, B. Lhermitte, M. E. Hegi, J. Rosell, R. Henriksson and G. Nordic Clinical Brain Tumour Study. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The Lancet Oncol 2012;13(9): 916-926.
  6. Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., Reifenberger, G. MGMT testing in neurooncology - A paradigm for prospects and challenges of biomarker-based treatment decisions. Nat Rev Neurol 2014;10:372-85.
  7. van den Bent, M. J., A. A. Brandes, M. J. Taphoorn, J. M. Kros, M. C. Kouwenhoven, J. Y. Delattre, H. J. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, R. H. Enting, P. J. French, W. N. Dinjens, C. J. Vecht, A. Allgeier, D. Lacombe, T. Gorlia and K. Hoang-Xuan. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31(3): 344-350.
  8. Cairncross, G., M. Wang, E. Shaw, R. Jenkins, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperriere, W. Curran and M. Mehta. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31(3): 337-343.
  9. Weller, M., M. van den Bent, K. Hopkins, J. C. Tonn, R. Stupp, A. Falini, E. Cohen-Jonathan-Moyal, D. Frappaz, R. Henriksson, C. Balana, O. Chinot, Z. Ram, G. Reifenberger, R. Soffietti, W. Wick and G. European Association for Neuro-Oncology Task Force on Malignant . EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014;15(9): e395-403.
  10. Wiestler, B., Capper, D., Sill, M., Jones, D.T., et al.. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014;128(4): 561-571.
  11. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F. Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics 2015;47, 458-68.
  12. Cancer Genome Atlas Resaerch Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl. J Med. 2015;372:2481-2498.
  13. Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Loffler-Wirth H, Kaulich K.et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015
  14. Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde T, Selt F, Sturm D, Kool M, Hummel M, Bewerunge-Hudler M, Mawrin C, Schüller U, Jungk C, Wick A, Witt O, Platten M, Herold-Mende C, Unterberg A, Pfister SM, Wick W, von Deimling A. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2015 Dec 15
  15. Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A. Progression types after anti-angiogenic therapy are related to outcome in recurrent glioblastoma. Neurology April 11 2014
  16. Choi, C., S. Ganji, K. Hulsey, A. Madan, Z. Kovacs, I. Dimitrov, S. Zhang, K. Pichumani, D. Mendelsohn, B. Mickey, C. Malloy, R. Bachoo, R. Deberardinis and E. Maher. "A comparative study of short- and long-TE (1)H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors." NMR Biomed 2013;26(10): 1242-1250.
  17. Schumacher T, Bunse L, Pusch S et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014;512:324-327
  18. Chinot OL, Wick W, Mason W et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England Journal of Medicine 2014;370:709-722
  19. Gilbert MR, Dignam JJ, Armstrong TS et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine 2014;370:699-708
  20. Herrlinger U, Schaefer N, Steinbach JP et al. Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients. ASCO Meeting Abstracts 2014;32:2042
  21. Taal, W., Oosterkamp, H.M., Walenkamp, A.M., Dubbink, H.J., Beerepoot, L.V., Hanse, M.C., Buter, J., Honkoop, A.H., Boerman, D., de Vos, F.Y., Dinjens, W.N., Enting, R.H., Taphoorn, M.J., van den Berkmortel, F.W., Jansen R.L., Brandsma, D., Bromberg, J.E., van Heuvel, I., Vernhout, R.M., van der Holt, B., van den Bent, M.J. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-53.
  22. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015;314(23):2535-43.

Strahlentherapie in der Neuroonkologie – Übersicht und aktuelle Entwicklungen

Oliver Oehlke, Anca-Ligia Grosu (S. 15-19)

 

  1. Le Rhun E, Taillibert S, Chamberlain MC. Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. Curr Neurol Neurosci Rep. 2016 Feb;16(2):15.
  2. Grosu AL, Oehlke O, Nieder C. Chapter 1 – Brain Tumors. In: Target Volume Definition in Radiation Oncology, Springer-Verlag Berlin Heidelberg, 2015.
  3. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009 Dec 10;27(35):5874-80.
  4. Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, Grosu AL, Lagerwaard FJ, Minniti G, Mirimanoff RO, Ricardi U, Short SC, Weber DC, Belka C. ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol. 2016 Jan;118(1):35-42.
  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.
  6. Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9.
  7. Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol. 2010 Sep;96(3):325-7.
  8. Götz I, Grosu AL. [(18)F]FET-PET Imaging for Treatment and Response Monitoring of Radiation Therapy in Malignant Glioma Patients - A Review. Front Oncol. 2013 Apr 25;3:104.
  9. Nieder C, Grosu AL. Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. Radiat Oncol. 2014 Jul 12;9:155.
  10. Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M, Grosu AL, Guckenberger M. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol. 2014 Jun;190(6):521-32.
  11. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011 Jan 10;29(2):134-4.
  12. Bilger A, Milanovic D, Lorenz H, Oehlke O, Urbach H, Schmucker M, Weyerbrock A, Nieder C, Grosu AL. Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. Clin Neurol Neurosurg. 2016 Jan 14;142:81-86.
  13. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov;10(11):1037-4.
  14. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, Shi W, Wendland M, Kachnic L, Mehta MP. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014 Dec 1;32(34):3810-6.
  15. Prokic V, Wiedenmann N, Fels F, Schmucker M, Nieder C, Grosu AL. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):264-70.
  16. Oehlke O, Wucherpfennig D, Fels F, Frings L, Egger K, Weyerbrock A, Prokic V, Nieder C, Grosu AL. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: Local tumour control and survival. Strahlenther Onkol. 2015 Jun;191(6):461-9.

Hirnmetastasen – Moderne Behandlungskonzepte

Weyerbrock Astrid (S. 20-22)

 

  1. Preusser M, Capper D, Ilhan-Mutlu A, et al. Brain metastases: pathobiology and emerging targeted therapies.  Acta Neuropathol 2012; 123: 205-22.
  2. Leitlinie „Hirnmetastasen und Meningeosis neoplastica“, AWMF-Nr. 030/060, online auf www.dgn.org seit Dezember 2014
  3. Lim CS and Grundy PL. Effectiveness and outcomes of surgery for brain metastases. Brit J Neurosurg 2013; 27(5): 654-7.
  4. Schackert G, Schmiedel K, Lindner C, et al. Surgery for recurrent brain metastases: retrospective analysis of 67 patients. Acta Neurochir 2013; 155(10): 1823-32.
  5. Soon YY, Tham IWK, Lim KH, Koh WY, Lu JJ. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases (review). Cochrane Library 2014, issue 3
  6. Soffietti R, Kocher M, Abacioglu U; et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 2013; 31(1): 65-72.
  7. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance oft he hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG): A phase II multi-institutional trial, J Clin Oncol 2014; 32: 3810-16.
  8. Moraes FY, Taunk NK, Marta GN, et al. The rationale for targeted therapies and stereotactic radiosurgery in the treatment of brain metastases. The Oncologist 2016; 21: 1-8.
  9. Lin X and DeAngelis LM. Treatment of Brain Metastases. J Clin Oncol 2015; 33(30): 3475-84.
  10. Margolin K, Ernstoff MS, Hamid O, Lawrence D et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-65.
  11. Long GV, Trefzer U, Davies MA, Kefford RF et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastastic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-95.
  12. Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 2016; 34(2): 123-129.
  13. Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 2015; 5(11): 1164-77.
  14. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30(4): 419-25.
  15. Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 2015; 16: e270-78.

Neuroonkologische Chirurgie – Wichtige Indikationen und Techniken

Niklas Thon, Jörg-Christian Tonn (S. 24-27)

 

  1. Eigenbrod S, Trabold R, Brucker D, et al. Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta neurochirurgica. Aug 2014;156(8):1427-1440.
  2. Thon N, Eigenbrod S, Grasbon-Frodl EM, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. Journal of neuropathology and experimental neurology. Nov 2009;68(11):1219-1228.
  3. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-oncology. Mar 2011;13(3):307-316.
  4. Tonn JC, Thon N, Schnell O, Kreth FW. Personalized surgical therapy. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. Sep 2012;23 Suppl 10:x28-32.
  5. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. Journal of neurosurgery. Jul 2011;115(1):3-8.
  6. Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. Dec 2013;24(12):3117-3123.
  7. Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncology. Jan 2014;16(1):81-91.
  8. Suchorska B, Weller M, Tabatabai G, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-oncology. Jan 27 2016.
  9. Suchorska B, Jansen NL, Linn J, et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. Feb 17 2015;84(7):710-719.
  10. Patel AJ, Suki D, Hatiboglu MA, et al. Factors influencing the risk of local recurrence after resection of a single brain metastasis. Journal of neurosurgery. Aug 2010;113(2):181-189.
  11. Kamp MA, Rapp M, Slotty PJ, et al. Incidence of local in-brain progression after supramarginal resection of cerebral metastases. Acta neurochirurgica. Jun 2015;157(6):905-910; discussion 910-901.
  12. Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Mar 2015;56(3):347-353.
  13. Schwarz SB, Thon N, Nikolajek K, et al. Iodine-125 brachytherapy for brain tumours--a review. Radiat Oncol. 2012;7:30.
  14. Schwartz C, Romagna A, Thon N, et al. Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas. Acta neurochirurgica. Oct 2015;157(10):1757-1764; discussion 1764.
  15. Schnell O, Scholler K, Ruge M, Siefert A, Tonn JC, Kreth FW. Surgical resection plus stereotactic 125I brachytherapy in adult patients with eloquently located supratentorial WHO grade II glioma - feasibility and outcome of a combined local treatment concept. Journal of neurology. Oct 2008;255(10):1495-1502.
  16. Stoecklein VM, Faber F, Koch M, et al. Optional real-time display of intraoperative neurophysiological monitoring in the microscopic field of view: avoiding communication failures in the operating room. Acta neurochirurgica. Nov 2015;157(11):1843-1847.
  17. Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of systematic reviews. 2014;1:CD009685.
  18. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. The Lancet. Oncology. Oct 2011;12(11):997-1003.
  19. Coburger J, Merkel A, Scherer M, et al. Low-Grade Glioma Surgery in Intraoperative Magnetic Resonance Imaging I: Results of a Multicenter Retrospective Assessment of the German Study Group for Intraoperative Magnetic Resonance Imaging. Neurosurgery. Oct 28 2015.
  20. Terpolilli NA, Rachinger W, Kunz M, et al. Orbit-associated tumors: navigation and control of resection using intraoperative computed tomography. Journal of neurosurgery. Nov 13 2015:1-9.

Gliome – Einteilung und Behandlungskonzepte

Tim Heiland, Marc-Eric Halatsch (S. 28-30)

 

  1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97-109.
  2. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14 Suppl 5: v1-49.
  3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90(19): 1473-9.
  4. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31(3): 337-43.
  5. Dubbink HJ, Atmodimedjo PN, Kros JM, et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol 2016; 18(3): 388-400.
  6. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27(35): 5874-80.
  7. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120(6): 707-18.
  8. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010; 6(1): 39-51.
  9. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10): 997-1003.
  10. Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol 2013; 15(8): 1017-26.
  11. ir.celldex.com/releasedetail.cfm
  12. clinicaltrials.gov/ct2/show/NCT01480479
  13. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011; 12(11): 997-1003.
  14. Brown PD, Buckner JC, O'Fallon JR, et al. Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial. Int J Radiat Oncol Biol Phys 2004; 58(4): 1153-60.
  15. Karim ABMF, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002; 52(2): 316-24.
  16. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996; 36(3): 549-56.
  17. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 2012; 30(25): 3065-70.
  18. Seystahl K, Wiestler B, Hundsberger T, et al. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 2013; 69(2): 95-101.
  19. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011; 28(4): 334-40.
  20. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7(5): 392-401.
  21. Bota DA, Alexandru-Abrams D, Pretto C, et al. Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. Perm J 2015; 19(2): 41-6.
  22. Polyzoidis S, Ashkan K. DCVax®-L—Developed by Northwest Biotherapeutics. Hum Vacc Immunother 2014; 10(11): 3139-45.
  23. Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 2015; 314(23): 2535-43.
  24. www.curebraincancer.org.au/page/175/about-gbm-agile

Update: Neue Behandlungsstrategien des metastasierten Nierenzellkarzinoms

Christian Doehn (S. 40-45)

 

  1. www.leitlinienprogramm-onkologie.de/Nierenzellkarzinom.85.0.html (aufgerufen am 23.3.2016)
  2. www.seer.cancer.gov (aufgerufen am 23.3.2016)
  3. Thoenes W, Störkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas, and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Path Res Pract. 1986;181: 125-143.
  4. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6: 655-663.
  5. Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol. 2007;177: 430-436.
  6. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P; ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37: 1469-1489.
  7. Pagano S, Franzoso F, Ruggeri P. Renal cell carcinoma metastases. Review of unusual clinical metastases, metastatic modes and patterns and comparison between clinical and autopsy metastatic series. Scand J Urol Nephrol. 1996;30: 165-172.
  8. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995;22: 42-60. 
  9. Lilleby W, Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol. 2005;23: 175-179.
  10. Mickisch GH. Chemoresistance of renal cell carcinoma: 1986-1994. World J Urol. 1994;12: 214-223.
  11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356: 115-124.
  12. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
  13. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28: 2144-2150.
  14. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. J Clin Oncol. 2010;28: 1061-1068.
  15. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369: 722-731.
  16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-2281.
  17. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14: 552-562.
  18. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD?1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116: 4256-4265.
  19. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356: 125-134.
  20. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32: 760-767.
  21. Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eur Urol. 2015;68: 837-847.
  22. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32: 2765-2772.
  23. Iacovelli R, Farcomeni A, Sternberg CN, Cartenì G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Maria Ruggeri E, Berruti A, Procopio G. Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. J Urol. 2015;193: 1905-1910.
  24. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373: 1803-1813.
  25. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373: 1814-1823.

Pharmaservice - Supportivtherapie: Einfache leitliniengerechte Prävention von CINV

(S.56)

 

  1. Lindley CM et al. Qual Life Res 1992; 1: 331-40
  2. O’Brien BJ et al. Can Med Assoc J 1993; 149: 296-302
  3. Noonan KA Adv Stud Nurs 2005; 3: 16-21
  4. Hesketh PJ et al. Ann Oncol 2014; 25: 1340-6
  5. Aapro M et al. Ann Oncol 2014; 25: 1328-1333
  6. Gralla RJ et al. Ann Oncol 2014; 25: 1333-1339
  7. Version 2.2015; 09/22/15 National Comprehensive Cancer Network
  8. Hesketh PJ et al. J Clin Oncol 2016; 34(4): 381-6
  9. www.mascc.org/antiemetic-guidelines